Hematology

Bidirectional endoscopy (upper endoscopy and colonoscopy) was underutilized in the evaluation of new-onset iron deficiency anemia in younger veterans from 2005 to 2019.

Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.

Taiho submitted the supplemental new drug application in April 2025 for decitabine/cedazuridine and venetoclax, and the FDA accepted it for review in July 2025.

Pediatric Sequential Organ Failure Assessment may better predict death in ALL and sepsis, supporting earlier ICU intervention.

Community pharmacists must build scalable workflows as bispecific antibodies move into earlier lines and outpatient settings, notes Brooke Peters, PharmD, BCOP, of AON.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence treatment decisions, says Kerry Rogers, MD.

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

A faster, cheaper alternative to karyotyping, DNA index testing shows near-perfect accuracy for detecting high hyperdiploidy in pediatric patients with leukemia.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left untreated.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.